Clinical observation of sacituzumab tirumotecan combined with bevacizumab in the treatment of HER2-negative breast cancer with brain metastases
- VernacularTitle:芦康沙妥珠单抗联合贝伐珠单抗治疗HER2－乳腺癌脑转移的临床观察
- Author:
Yufeng YANG
1
;
Xiuli YANG
2
;
Peng CHENG
2
;
Ling SHEN
2
;
Qian YANG
2
;
Yingbo SHAO
3
Author Information
1. Dept. of Pharmacy，The First Affiliated Hospital of Nanyang Medical College，Henan Nanyang 473003，China
2. Dept. of Oncology，The First Affiliated Hospital of Nanyang Medical College，Henan Nanyang 473003，China
3. Dept. of Breast Surgery，Henan Provincial People’s Hospital，Zhengzhou 450003，China
- Publication Type:Journal Article
- Keywords:
Breast cancer;
HER2－;
brain metastases;
sacituzumab tirumotecan;
bevacizumab;
Efficacy;
Safety
- From:
China Pharmacy
2026;37(16):2156-2160
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To evaluate the efficacy and safety of sacituzumab tirumotecan combined with bevacizumab for the treatment of human epidermal growth factor receptor 2-negative （HER2－） breast cancer with brain metastases.METHODS Clinical data of 90 patients with HER2－ breast cancer with brain metastases treated at the First Affiliated Hospital of Nanyang Medical College from December 2024 to November 2025 were retrospectively collected. According to the treatment regimens， the patients were divided into a control group （ n ＝55） and an experimental group （ n ＝35）. Patients in the experimental group received sacituzumab tirumotecan combined with bevacizumab， whereas those in the control group received conventional systemic therapy， including albumin-bound paclitaxel-based regimens， capecitabine-based regimens， or gemcitabine/vinorelbine combined with platinum-based regimens. Short-term efficacy， progression-free survival （PFS）， brain metastasis-related efficacy， adverse events， treatment discontinuation due to adverse events， and treatment-related deaths were compared between the two groups.RESULTS The objective response rate （ORR）， disease control rate， median PFS， intracranial disease control rate， and proportion of patients with improvement in neurological symptoms in the experimental group were significantly higher than in the control group （ P ＜0.05）. Stratified analysis showed that PFS of the experimental group was significantly longer than the control group among patients with Breast-Graded Prognostic Assessment scores ≥2.0 and ＜2.0 （ P ＜0.05）. There were no statistically significant differences in the proportion of patients with glucocorticoid dose reduction/discontinuation， the incidence of adverse events of different grades， or the rate of treatment discontinuation due to adverse events between the two groups （ P ＞0.05）. No treatment-related deaths occurred in either group.CONCLUSIONS Compared with conventional systemic therapy， sacituzumab tirumotecan combined with bevacizumab can improve the ORR and prolong PFS in patients with HER2－ breast cancer with brain metastases， with an overall manageable safety profile.
